Vioxx should be allowed back on the market advises expert panel

Sibbald, Barbara
August 2006
CMAJ: Canadian Medical Association Journal;8/1/2006, Vol. 175 Issue 3, p234
Academic Journal
Focuses on a recommendation issued by Health Canada's Expert Advisory Panel on the Safety of COX-2 Selective Non-steroidal Anti-Inflammatory Drugs (NSAIDS) to return Rofecoxib drug into the market. Findings of an analysis on the cardiovascular risks associated with cyclooxygenase 2-selective NSAIDS; Physiological effect of Rofecoxib; Decision of Health Canada on the recommendation.


Related Articles

  • Balancing the cyclooxygenase portfolio. Armstrong, Paul W. // CMAJ: Canadian Medical Association Journal;5/23/2006, Vol. 174 Issue 11, p1581 

    Presents an opinion on issues associated with the introduction and withdrawal from general use of rofecoxib (Vioxx), a selective cyclooxygenase (COX)-2 inhibitor. Overview its mechanism of action; Risk associated with rofecoxib in elderly patients; Recommendation given by an expert advisory...

  • Unmet Needs in Non-steroidal Anti-inflammatory Drug-induced Upper Gastrointestinal Diseases. Scheiman, James M. // Drugs;2006 Supplement 1, Vol. 66, p15 

    The use of traditional and cyclooxygenase (COX)-2-selective non-steroidal antiinflammatory drugs (NSAID) for the relief of pain and inflammation increases the risk of gastrointestinal side-effects ranging from dyspepsia to symptomatic and complicated ulcers. The COX-2-selective agents were...

  • Cardiovascular AE risk not increased once off Vioxx.  // Reactions Weekly;5/20/2006, Issue 1102, p3 

    Presents the results of the preliminary analyses of the off-drug extension of the Adenomatous Polyp Prevention on Vioxx (APPROVe). Impact of rofecoxib, APPROVe on the risk of cardiovascular adverse event in patients who had previously received Vioxx; Myocardial infarction and stroke among...

  • Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients. Liffert Vogt; Dick de Zeeuw; Arend Jan J. Woittiez; Gerjan Navis // Nephrology Dialysis Transplantation;Apr2009, Vol. 24 Issue 4, p1182 

    Background. Renoprotection is predicted by the antiproteinuric efficacy of a pharmacological agent. Non-steroidal anti-inflammatory drugs (NSAIDs) interfering non-selectively in the prostaglandin system have strong antiproteinuric potency without reduction of systemic blood pressure. The effect...

  • Cardiovascular Events Associated with Long-Term Use of Celecoxib, Rofecoxib and Meloxicam in Taiwan: An Observational Study. Weng-Foung Huang; Fei-Yuan Hsiao; Yi-Wen Tsai; Yu-Wen Wen; Yaw-Tang Shih // Drug Safety;2006, Vol. 29 Issue 3, p261 

    BACKGROUND: Using national data (2001–2003), this study explored the risk of acute myocardial infarction (AMI), angina, stroke and transient ischaemic attack (TIA) in long-term users of rofecoxib and celecoxib in Taiwan and compared this data with that for those using meloxicam....

  • Tailoring Arthritis Therapy in the Wake of the NSAID Crisis. Olsen, Nancy J. // New England Journal of Medicine;6/23/2005, Vol. 352 Issue 25, p2578 

    This article presents an editorial on arthritis therapy and nonsteroidal anti-inflammatory agents (NSAIDs). The author discusses how the controversy over the safety of the drugs rofecoxib and valdecoxib and naproxen have made it difficult to decide on drug prescriptions for arthritic patients....

  • COX-2 Inhibitors, Other NSAIDs, and Cardiovascular Risk. Graham, David J. // JAMA: Journal of the American Medical Association;10/4/2006, Vol. 296 Issue 13, p1653 

    The article discusses how doctors and the U. S. Food and Drug Administration were led to approve nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors in spite of evidence that they caused cardiovascular side-effects. Soon after its release, studies showed that rofecoxib reduced...

  • NSAID prescriptions plunge following product withdrawal.  // Reactions Weekly;7/14/2007, Issue 1160, p4 

    The article reports on a study which found a decrease in prescriptions for nonsteroidal anti-inflammatory agents (NSAID) after the release of postmarketing safety data and the subsequent withdrawal of rofecoxib and valdecoxib from the market. Dispensing claims from a single insurance company for...

  • Progress in COX-2 Inhibitors: A Journey So Far. Chakraborti, Asit K.; Garg, Sanjeev K.; Kumar, Raj; Motiwala, Hashim F.; Jadhavar, Pradeep S. // Current Medicinal Chemistry;May2010, Vol. 17 Issue 15, p1563 

    The non-steroidal anti-inflammatory drugs (NSAIDs) are diverse group of compounds used for the treatment of inflammation, since the introduction of acetylsalicylic acid in 1899. Traditional (first generation) NSAIDs exert anti-inflammatory, analgesic, and antipyretic effects through the blockade...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics